Hans-Jörg Kirner

Title: The Innovations of Hans-Jörg Kirner

Introduction

Hans-Jörg Kirner is a notable inventor based in Pratteln, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of polymorphic forms of sertraline hydrochloride. With a total of 2 patents to his name, Kirner's work has the potential to enhance drug absorption rates, which is crucial for effective medication.

Latest Patents

Kirner's latest patents focus on the polymorphic forms of sertraline hydrochloride. One of his key inventions is a crystalline form referred to as polymorphic form CSC2, which exhibits a dissolution rate that surprisingly increases the absorption rate of the drug. Additionally, he has disclosed various crystalline forms of sertraline hydrochloride alcohol solvates and hydrates, including polymorphic form CSC1. His patents also cover processes for preparing the amorphous form of sertraline hydrochloride and different polymorphic forms I, II, V, and T1.

Career Highlights

Hans-Jörg Kirner is associated with Ciba Specialty Chemicals Corporation, where he has been instrumental in advancing pharmaceutical innovations. His expertise in the field has led to the development of new formulations that can significantly impact patient care and treatment outcomes.

Collaborations

Throughout his career, Kirner has collaborated with esteemed colleagues such as Paul Adriaan Van Der Schaaf and Franz Schwarzenbach. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Hans-Jörg Kirner's contributions to the pharmaceutical industry through his patents on sertraline hydrochloride polymorphs demonstrate his commitment to enhancing drug efficacy. His work continues to influence the field and improve therapeutic options for patients.